Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics

MENLO PARK, Calif.--(BUSINESS WIRE)-- #Synthekine--Synthekine Inc., an engineered cytokine therapeutics company, today announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors. Debanjan Ray, Synthekine’s chief executive officer, will present a corporate overview at the 41st Annual...

Click to view original post